Pulmonary arterial hypertension (PAH) is a rare, progressive disorder impacting small pulmonary arteries, leading to increased vascular resistance and heart failure. The latest report forecasts ...

The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...

There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

The disease primarily affects middle-aged women and has a poor long-term prognosis despite therapeutic advances.

Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM) is projected to reach $9.3b by 2034, ...

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

Memorial Using Tech to Help Patients Monitor Vitals at Home A 30-second, at-home test can alert those with pre-existing cardiac conditions to abnormalities within their heart before the onset of any ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...